Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
Phase I Alimta Combination With BMS-275183 (Oral Taxane)
1 other identifier
interventional
N/A
2 countries
3
Brief Summary
A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 15, 2005
CompletedFirst Posted
Study publicly available on registry
February 16, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2005
CompletedMarch 2, 2010
August 1, 2008
February 15, 2005
February 27, 2010
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Advanced or metastatic pretreated NSCLC
- Measurable disease
- Adequate hematologic, hepatic and renal functions.
- ECOG Performance Status 0-2
You may not qualify if:
- Inability to swallow capsules
- Recent significant cardiovascular disease
- Women who are pregnant or breastfeeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Local Institution
Denver, Colorado, United States
Local Institution
Rochester, Minnesota, United States
Local Institution
Toronto, Ontario, Canada